3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma
74
Lymphoma, Large B-Cell, Diffuse
55
Lymphoma, Non-Hodgkin
54
Lymphoma, Mantle-Cell
40
Lymphoma, Follicular
37
Hodgkin Disease
36
Lymphoma, Large-Cell, Immunoblastic
26
Burkitt Lymphoma
25
Leukemia, Lymphocytic, Chronic, B-Cell
22
Precursor Cell Lymphoblastic Leukemia-Lymphoma
20
Lymphoma, B-Cell, Marginal Zone
15
Leukemia
10
Recurrence
9
Lymphoma, B-Cell
9
Lymphoma, T-Cell
8
Multiple Myeloma
7
Waldenstrom Macroglobulinemia
6
Neoplasms, Plasma Cell
6
Lymphoma, T-Cell, Cutaneous
6
Lymphoma, T-Cell, Peripheral
5
Lymphoma, Large-Cell, Anaplastic
5
Leukemia, Myeloid, Acute
5
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
4
Dendritic Cell Sarcoma, Interdigitating
4
Congenital Abnormalities
4
Myelodysplastic Syndromes
3
Leukemia, Myeloid, Chronic-Phase
3
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
3
Leukemia, Myeloid, Accelerated Phase
3
Blast Crisis
3
Interventions
Cyclophosphamide
13
fludarabine
9
fludarabine phosphate
7
Bendamustine Hydrochloride
5
Rituximab
4
Busulfan
4
ibrutinib
3
Tacrolimus
3
Mycophenolic Acid
3
Melphalan
3
Bortezomib
3
AP 1903 reagent
3
tetulomab tetraxetan lu-177
2
ponatinib
2
cobomarsen
2
Whole-Body Irradiation
2
Vorinostat
2
Vincristine
2
Prednisone
2
Peripheral Blood Stem Cell Transplantation
2
Patient Reported Outcome Measures
2
Mesna
2
Lutetium
2
Etoposide
2
Doxorubicin
2
Brentuximab Vedotin
2
Bone Marrow Transplantation
2
pembrolizumab
1
ibritumomab tiuxetan
1
enzalutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Immune System Diseases
×
Carmustine
×
Lymphoid
×
Clear all
NCT02366663
2018-03-12
SPINOZA
City of Hope Medical Center
Phase 3
Terminated
3 enrolled
8 charts